JINTROPIN (Somatropin) was developed as a genetically engineered growth hormone (HGH). It affects the metabolic processes and also provides stimulation of skeletal and somatic growth. JINTROPIN promotes stimulation of growth of bones of a skeleton, as a result of influence on plates of an epiphysis of long bones, bone metabolism. The body structure is normalized by reducing fat mass and increasing muscle mass.
During substitution therapy at patients with osteoporosis and lack of growth hormone, JINTROPIN occurs normalization of mineral composition and bone density. It promotes increase in number and the size of cells of muscles, a liver, a thymus gland, sexual glands, adrenal glands, thyroid gland.
JINTROPIN initiates delivery of amino acids to the cell and protein synthesis, cholesterol level, affecting the profile of lipids and lipoproteins. It suppresses insulin release. It promotes the retention of sodium, potassium and phosphorus. JINTROPIN increases body weight, muscle activity and physical endurance.